首页> 外文期刊>BMC Women s Health >Independent external validation of cardiovascular disease mortality in women utilising Framingham and SCORE risk models: a mortality follow-up study
【24h】

Independent external validation of cardiovascular disease mortality in women utilising Framingham and SCORE risk models: a mortality follow-up study

机译:利用Framingham和SCORE风险模型对妇女的心血管疾病死亡率进行外部独立验证:一项死亡率随访研究

获取原文
       

摘要

Background We conducted an independent external validation of three cardiovascular risk score models (Framingham risk score model and SCORE risk charts developed for low-risk regions and high-risk regions in Europe) on a prospective cohort of 4487 Australian women with no previous history of heart disease, diabetes or stroke. External validation is an important step to evaluate the performance of risk score models using discrimination and calibration measures to ensure their applicability beyond the settings in which they were developed. Methods Ten year mortality follow-up of 4487 Australian adult women from the National Heart Foundation third Risk Factor Prevalence Study with no baseline history of heart disease, diabetes or stroke. The 10-year risk of cardiovascular mortality was calculated using the Framingham and SCORE models and the predictive accuracy of the three risk score models were assessed using both discrimination and calibration. Results The discriminative ability of the Framingham and SCORE models were good (area under the curve?>?0.85). Although all models overestimated the number of cardiovascular deaths by greater than 15%, the Hosmer-Lemeshow test indicated that the Framingham and SCORE-Low models were calibrated and hence suitable for predicting the 10-year cardiovascular mortality risk in this Australian population. An assessment of the treatment thresholds for each of the three models in identifying participants recommended for treatment were found to be inadequate, with low sensitivity and high specificity resulting from the high recommended thresholds. Lower treatment thresholds of 8.7% for the Framingham model, 0.8% for the SCORE-Low model and 1.3% for the SCORE-High model were identified for each model using the Youden index, at greater than 78% sensitivity and 80% specificity. Conclusions Framingham risk score model and SCORE risk chart for low-risk regions are recommended for use in the Australian women population for predicting the 10-year cardiovascular mortality risk. These models demonstrate good discrimination and calibration performance. Lower treatment thresholds are proposed for better identification of individuals for treatment.
机译:背景我们对4487名没有心脏病史的澳大利亚妇女进行了前瞻性队列研究,对这三种心血管疾病风险评分模型(针对欧洲的低风险地区和高风险地区开发的Framingham风险评分模型和SCORE风险图表)进行了独立的外部验证。疾病,糖尿病或中风。外部验证是使用判别和校准措施评估风险评分模型的性能的重要步骤,以确保其适用性超出其开发环境。方法:美国国家心脏基金会第三次危险因素患病率研究对4487名澳大利亚成年女性进行了10年死亡率随访,没有心脏病,糖尿病或中风的基线病史。使用Framingham和SCORE模型计算了10年的心血管疾病死亡风险,并使用判别和校准对三种风险评分模型的预测准确性进行了评估。结果Framingham模型和SCORE模型的判别能力良好(曲线下面积≥0.85)。尽管所有模型均高估了超过15%的心血管死亡人数,但Hosmer-Lemeshow测试表明Framingham和SCORE-Low模型已经过校准,因此适合预测该澳大利亚人群10年心血管死亡的风险。发现在确定推荐治疗的参与者时,对三种模型中每种模型的治疗阈值评估均不充分,其高推荐阈值导致敏感性低和特异性高。对于每个模型,使用Youden指数确定的较低治疗阈值分别为Framingham模型的8.7%,SCORE-Low模型的0.8%和SCORE-High模型的1.3%,灵敏度高于78%,特异性为80%。结论建议将低风险地区的Framingham风险评分模型和SCORE风险表用于澳大利亚女性人群,以预测10年心血管疾病的死亡风险。这些模型显示出良好的辨别力和校准性能。建议较低的治疗阈值,以更好地识别要治疗的个体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号